Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine.

Singh, Balraj; Sarli, Vanessa N; Lucci, Anthony

Singh, Balraj; Sarli, Vanessa N; Lucci, Anthony.

Afiliação

Singh B; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sarli VN; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lucci A; Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Oncotarget ; 12(7): 626-637, 2021 Mar 30.

Article em En | MEDLINE | ID: mdl-33868584

Palavras-chave

breast cancer relapse; intratumor heterogeneity; metastasis prevention; minimal residual disease; resistant TNBC

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google